Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer

[1]  P. Crowell.  Monoterpenes in breast cancer chemoprevention , 1997, Breast Cancer Research and Treatment.

[2]  A. Adjei,et al.  Farnesyl transferase inhibitors as anticancer agents. , 2002, European journal of cancer.

[3]  S. Wadler,et al.  A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. , 2002, Gynecologic oncology.

[4]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[5]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[6]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[8]  M. You,et al.  CHEMOPREVENTIVE EFFICACY OF PROMISING FARNESYLTRANSFERASE INHIBITORS , 2000, Experimental lung research.

[9]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[11]  M. Ellis,et al.  Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. , 1999, Cancer research.

[12]  R. Gibbs,et al.  Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors. , 1999, Bioorganic & medicinal chemistry.

[13]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[14]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[15]  A. Qureshi,et al.  Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. , 1997, The Journal of nutrition.

[16]  V. Steele,et al.  Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. , 1997, Cancer research.

[17]  R. Hohl.  Monoterpenes as regulators of malignant cell proliferation. , 1996, Advances in experimental medicine and biology.

[18]  F. Tamanoi,et al.  The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. , 1995, Cancer letters.

[19]  R. Jirtle,et al.  Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. , 1995, Cancer research.

[20]  C. Der,et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Gould,et al.  Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. , 1991, The Journal of biological chemistry.